ArticleBiochemical genetics2026
Salidroside Regulates DN Podocyte Injury Through the LncRNA ZEB1-AS1/miR-21-5p/PDCD4 Axis.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Salidroside (SAL) is a drug supplement with cytoprotective properties that can relieve the effects of diabetes-related complications. This study aims to investigate the function of SAL in diabetic nephropathy (DN). The expression of related genes and proteins was detected by RT-qPCR, western blot, immunofluorescence and immunohistochemistry. Cell proliferation and apoptosis were detected by CCK-8 and TUNEL. HE, Masson and PAS staining were used to evaluate the pathological changes of kidney in DN rats. The results showed that SAL suppressed miR-21-5p expression by upregulating lncRNA ZEB1-AS1(ZEB1-AS1) and thus promoting PDCD4 expression, inhibiting cell apoptosis, promoting podocyte proliferation and migration, and alleviating podocyte injury in DN. Further in vivo experiments demonstrated that SAL-treated rats exhibited decreases in blood urine nitrogen (BUN) and the urine albumin–creatinine ratio (ACR), and SAL ameliorated the severity of DN, while knocking down ZEB1-AS1 weakened the effect of SAL. Our data suggested that the upregulation of ZEB1-AS1 by SAL participated in the ceRNA network and had a key function in alleviating DN podocyte injury through ZEB1-AS1-miR-21-5p-PDCD4 crosstalk. In conclusion, this study demonstrated that SAL inhibited DN podocyte injury through the ZEB1-AS1/miR-21-5p/PDCD4 axis.
Indexed as
Identifiers
41964739What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.